Browsing by Author "Eser B."
Now showing 1 - 7 of 7
Results Per Page
Sort Options
Item Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience(John Wiley and Sons Ltd, 2018) Gemici A.; Aydogdu I.; Terzi H.; Sencan M.; Aslan A.; Kaya A.H.; Dal M.S.; Akay M.O.; Dogu M.H.; Ayyildiz O.; Sahin F.; Cagliyan G.A.; Yilmaz M.; Gokgoz Z.; Bilen Y.; Demir C.; Sevindik O.G.; Korkmaz S.; Eser B.; Altuntas F.Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey. We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty-three patients were included in the study. Median age of patients was 37.5 years (18-70) at the time of diagnosis. About 60.5% patients were diagnosed as stage I and II NLPHL, and remaining 39.5% had stage III and IV disease. Median follow-up was 46 months. During follow-up, none of the patients died. Seven patients relapsed or progressed after initial therapy at a median of 12 months. Five of 7 relapsed/refractory patients (71.4%) were salvaged with chemotherapy only (DHAP, ICE), and the remaining 2 (28.6%) were salvaged with chemoimmunotherapy. All of relapsed/refractory patients were able to achieve complete remission after salvage therapy. Lactate dehydrogenase levels were significantly higher in patients with progressive disease compared with nonprogressive disease. Our study showed an excellent outcome with all patients alive at last contact with a median follow up of 46 months despite a wide range of different therapeutic approaches. All relapsed and refractory patients were successfully salvaged despite a low frequency of patients received immunotherapy in conjunction with chemotherapy. Our results suggest that immunotherapy may be reserved for further relapses. Copyright © 2017 John Wiley & Sons, Ltd.Item Pralatrexate experience in peripheral T-cell lymphoma: A multicenter retrospective study from Turkey(Zerbinis Publications, 2021) Dal M.S.; Merdin A.; Erkurt M.A.; Ekinci Ö.; Albayrak M.; Hacıoglu S.K.; Kaya A.; Dogu M.H.; Hindilerden F.; Sarici A.; Merter M.; Aras M.R.; Caglıyan G.A.; Cakar M.K.; Aydogdu I.; Kuku I.; Korkmaz S.; Ulas T.; Eser B.; Altuntas F.Purpose: Pralatrexate is a new generation antifolate treatment agent used for the treatment of relapsed or refractory peripheral T-cell lymphomas. This study aims to determine the general characteristics of the patients receiving pralatrexate therapy in Turkey, contributing to the literature on the effectiveness of pralatrexate therapy in peripheral T-cell lymphomas by determining the response levels of such patients to the therapy. The study also attempts to clinically examine the major side effects observed in patients during treatment with pralatrexate. Methods: The study included patients with peripheral T-cell lymphoma followed up in the hematology units of several hospitals in Turkey. Overall, 20 patients aged 18 and over were included in the study. Results: The median age at the time of diagnosis was 58.5 years. PTCL-NOS (Peripheral T-cell lymphoma, not otherwise specified) subtype was in 40% of patients, making the PTCL-NOS the most common subtype in the study. In general, most patients were diagnosed with disease at an advanced stage. Pralatrexate therapy was given to the patients at a median treatment line of 3.5. Pralatrexate dose reduction was required in only 3 patients (15%). Response to pralatrexate therapy with partial remission (PR) and above was observed in 11 (55%) of the patients. Conclusion: Pralatrexate seemed to be a promising novel treatment in relapsed refractory PTCL patients. However, patients receiving pralatrexate should be followed up carefully for skin reactions, mucosal side effects, thrombocytopenia and neutropenia. © 2021 Zerbinis Publications. All rights reserved.Item The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL(Elsevier Inc., 2022) Akpinar S.; Dogu M.H.; Celik S.; Ekinci O.; Hindilerden I.Y.; Dal M.S.; Davulcu E.A.; Tekinalp A.; Hindilerden F.; Ozcan B.G.; Hacibekiroglu T.; Erkurt M.A.; Bagci M.; Namdaroglu S.; Korkmaz G.; Bilgir O.; Cagliyan G.A.; Ozturk H.B.A.; Serin I.; Tiryaki T.O.; Ozatli D.; Korkmaz S.; Ulas T.; Eser B.; Turgut B.; Altuntas F.Introduction/Background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL in real-world settings. Patients/Methods: A total of 200 relapsed/refractory CLL patients with a median age of 68 were included in this retrospective, multicenter, non-interventional study. Data of the study were captured from the patient charts of the participating centers. Results: The median for lines of previous chemotherapy was 2 (1-6); 62 (31.8%) patients had del17p and/or p53 mutations (del17p+/p53mut). Of the study group, 146 (75%) patients achieved at least PR, while 16 (8.7%) patients discontinued ibrutinib due to TEA. The most common drug-related adverse events were neutropenia (n: 31; 17.4%) and thrombocytopenia (n: 40; 22.3%), which were ≥ grade 3 in 9 (5%) and 5 (3.9%) patients, respectively. Pneumonia (n: 42; 23.7%) was the most common nonhematologic TEA. Atrial fibrillation (n: 5; 2.8%) and bleeding (n: 11; 6.3%) were relatively rare during the study period. Within a median follow-up period of 17 (1-74) months, 42 (21%) patients died. The estimated median OS of the study cohort was 52 months. Only the response to ibrutinib (CR/PR vs. SD/PD) was significantly associated with OS. Conclusion: Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. © 2021 Elsevier Inc.Item The clinicopathological features and survival of Castleman disease: A multicenter Turkish study(Verduci Editore s.r.l, 2022) Yildiz J.; Bagci M.; Sayin S.; Kaya A.; Yilmaz F.; Ekinci O.; Dal M.S.; Basturk A.; Aydogdu I.; Albayrak M.; Dogan A.; Erkurt M.A.; Korkmaz S.; Ulas T.; Eser B.; Altuntas F.Objective: In this study, we aimed to investigate the clinicopathological features and survival of CD, which is quite rare and has many unknowns. Patients and Methods: This study was conducted by retrospectively evaluating patients diagnosed with CD in six different centers in Turkey. Results: The median age of 33 patients included in the study was 49 and 51.5% (n = 17) of these patients were women. 18 (54.5%) patients were in the hyaline vascular subtype and most of the patients were UCD (n = 20, 60.6%). The most common involvement region was head and neck (n = 19, 57.5%). The UCD group was younger than the MCD group (p=0.027). Visceral lymph node involvement was higher in MCD than in UCD (p=0.001). Similarly, it was observed that there was more hepatomegaly (p=0.035) and splenomegaly (p=0.013) in the MCD group. During the median 19.5 months follow-up period, there were no patients who died. Conclusions: It was observed that UCD and MCD are different clinical entities. Promising survival times can be achieved with surgical and systemic treatments in both subtypes of this extremely rare disease. However, this result should be supported by well-designed prospective comprehensive studies. © 2022 Verduci Editore s.r.l. All rights reserved.Item Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey(Taylor and Francis Ltd., 2023) Bakırtaş M.; Dal M.S.; Yiğenoğlu T.N.; Giden A.O.; Serin I.; Başcı S.; Kalpakci Y.; Korkmaz S.; Ekinci O.; Albayrak M.; Basturk A.; Ozatli D.; Dogu M.H.; Hacıbekiroglu T.; Çakar M.K.; Ulas T.; Miskioglu M.; Gulturk E.; Eser B.; Altuntas F.A multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least ≥ two lines of therapy. Patients’ treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.5 ± 9.1 years. There were 20 patients (37.0%) with progression. Median progression-free survival was 13 months in patients who received a median of three therapy lines in a 7.5-month follow-up period. Overall response rate was 38.5%. Of 54 patients, 19 (40.4%) had at least one adverse event, and nine (19.1%) had an adverse event of at least grade 3 or more. Of 72 adverse events observed in 47 patients, 68% were grade 1 or 2. Treatment was not stopped in any patient due to adverse events. IRd combination therapy was effective and safe in heavily treated RRMM patients. © 2023 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia (Italian Society of Chemotherapy).Item International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report(Elsevier Ltd, 2023) Ozatli D.; Giden A.O.; Erkurt M.A.; Korkmaz S.; Basci S.; Ulas T.; Turgut B.; Yigenoglu T.N.; Hacibekiroglu T.; Basturk A.; Dal M.S.; Namdaroglu S.; Hindilerden F.; Hacioglu S.K.; Cagliyan G.A.; Ilhan G.; Kacmaz M.; Uysal A.; Merter M.; Ekinci O.; Dursun F.E.; Tekinalp A.; Demircioglu S.; Sincan G.; Acik D.Y.; Akdeniz A.; Ucar M.A.; Yeral M.; Ciftciler R.; Teke H.U.; Umit E.G.; Karakus A.; Bilen Y.; Yokus O.; Albayrak M.; Demir C.; Okan V.; Serefhanoglu S.; Kartı S.; Ozkurt Z.N.; Eser B.; Aydogdu I.; Kuku I.; Cagirgan S.; Sonmez M.; Ozet G.; Altuntas F.Therapeutic apheresis is an extracorporeal treatment that selectively removes abnormal cells or harmful substances in the blood that are associated with or cause certain diseases. During the last decades the application of therapeutic apheresis has expanded to a broad spectrum of hematological and non-hematological diseases due to various studies on the clinical efficacy of this procedure. In this context there are more than 30 centers performing therapeutic apheresis and registered in the apheresis database in Turkey. Herein, we, The Turkish Apheresis Registry, aimed to analyze some key articles published so far from Turkey regarding the use of apheresis for various indications. © 2023 Elsevier LtdItem The effect of visual education aimed at the basic needs of individuals with disabilities on the health literacy and life quality of caregivers(Routledge, 2024) Açıl D.; Sevgi Dogan E.; Bilgin N.; Eser B.; Sengül N.; Mutlu B.; Sivecan H.; Sevener U.; Mizrak S.; Atli Ozbas A.; Erkus M.E.The aim of this research is to evaluate the effect of visual education for the basic needs of people with disabilities on the health literacy and life quality of caregivers. The study sample comprised 268 caregivers evaluated in a pretest-posttest pattern. The data were collected using a Personal Information Form, the Health Literacy Scale, and the World Health Organization [WHO] Life Quality Scale-Short Form. Data were evaluated with the Wilcoxon test and Spearman correlation analysis. Following the education given to caregivers, an increase was determined in the Health Literacy Scale sub-dimension of information comprehension and in the WHO Life Quality Scale-Short Form sub-dimension of social relations. Thus it was seen that the visual education increased the health literacy and life quality of the caregivers. © 2024 Taylor & Francis Group, LLC.